An H3K9/S10 methyl-phospho switch modulates Polycomb and Pol II binding at repressed genes during differentiation

Pierangela Sabbattini, Marcela Sjoberg, Svetlana Nikic, Alberto Frangini, Per-Henrik Holmqvist, Natalia Kunowska, Tom Carroll, Emily Brookes, Simon J. Arthur, Ana Pombo, and Niall Dillon

*Gene Regulation and Chromatin Group and *Genome Function Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN, United Kingdom; *MRC Protein Phosphorylation Unit, Sir James Black Centre, University of Dundee, Dundee DD1 5EH, United Kingdom

**ABSTRACT** Methylated histones H3K9 and H3K27 are canonical epigenetic silencing modifications in metazoan organisms, but the relationship between the two modifications has not been well characterized. H3K9me3 coexists with H3K27me3 in pluripotent and differentiated cells. However, we find that the functioning of H3K9me3 is altered by H3S10 phosphorylation in differentiated postmitotic osteoblasts and cycling B cells. Deposition of H3K9me3/S10ph at silent genes is partially mediated by the mitogen- and stress-activated kinases (MSK1/2) and the Aurora B kinase. Acquisition of H3K9me3/S10ph during differentiation correlates with loss of paused S5 phosphorylated RNA polymerase II, which is present on Polycomb-regulated genes in embryonic stem cells. Reduction of the levels of H3K9me3/S10ph by kinase inhibition results in increased binding of RNAPII S5ph and the H3K27 methyltransferase Ezh1 at silent promoters. Our results provide evidence of a novel developmentally regulated methyl-phospho switch that modulates Polycomb regulation in differentiated cells and stabilizes repressed states.

**INTRODUCTION** Differentiation of pluripotent stem cells into specialized lineages requires activation of specific gene expression programs and long-term silencing of genes that specify alternative cell fates. Epigenetic modifications of the core histones form complex combinations on nucleosomes that are believed to reinforce activating and silencing effects of transcription factors and participate in the maintenance of cellular memory of transcription states (Jenuwein and Allis, 2001; Turner, 2002). Methylations of lysines 9 and 27 (K9 and K27) of histone H3 are key modifications that have been associated mainly with transcriptional repression. Trimethyl H3K9 (H3K9me3) is well established as a marker for heterochromatin and acts as a binding site for heterochromatin protein 1 (HP1). Trimethyl H3K27 (H3K27me3) is associated with silencing by the Polycomb group (PcG) proteins. Domains of enrichment for H3K27me3 are widely distributed across developmentally regulated genes in pluripotent embryonic stem cells, and many of these regions coexist with the activating H3K4me3 modification to form bivalent domains, which are believed to be involved in poising genes for activation (Azuara et al., 2006; Bernstein et al., 2006a).

The PcG proteins form a number of different complexes in the nucleus, of which the best characterized are Polycomb repressor complex 1 and 2 (PRC1 and PRC2; reviewed by Sawarkar and Paro, 2010). The PRC2 proteins Ezh2 and Ezh1 are both able to methylate H3K27 to generate H3K27me3 and functionally substitute for one another at Polycomb-regulated genes (Shen et al., 2008; Ezhkova et al., 2011). Ezh2 is highly expressed early in development and in proliferating cells, with expression of Ezh1 increasing at later stages of differentiation. Recent studies also implicate Ezh1 and Ezh2 in...
gene activation. Ezh1 is required for transcription factor recruitment and transcriptional elongation in a myoblast differentiation model (Mousavi et al., 2011; Stojic et al., 2011), and the S21 phosphorylated (S21ph) form of Ezh2 is implicated in transcriptional activation in prostate cancer cells (Xu et al., 2012).

Components of the PRC1 and PRC2 complexes can bind to H3K27me3. This has the potential to form a forward loop, which would have the effect of amplifying and maintaining Polycomb silencing. A second enzymatic activity, which is associated with the PRC1 complex, is the ubiquitin ligase activity of RING1B. This results in ubiquitination of histone H2AK119, a modification that is associated with the presence of a paused serine 5–phosphorylated RNA polymerase II (RNAPIIS5ph) at bivalently marked genes in embryonic stem (ES) cells (Stock et al., 2007).

Although the interaction of the PcG proteins with H3K27me3 forms a central part of the current paradigm for the mechanism of Polycomb-mediated silencing, there is also evidence of a role for H3K9 methylation in Polycomb binding. Drosophila and mammalian Polycomb proteins have been shown to bind to H3K9me3 (Fischle et al., 2003b; Bernstein et al., 2006b; Margueron et al., 2009; Kaustov et al., 2011). Colocalization of H3K9me3 with H3K27me3 was observed at 48% of Polycomb-binding sites on Drosophila polytene chromosomes, and a H3 peptide containing the K9me3 residue was able to compete efficiently for Polycomb binding at a number of sites (Ringrose et al., 2004). A significant proportion (49%) of bivalent domains in murine ES cells have been shown to be marked by H3K9me3 (Bilodeau et al., 2009). The presence of the H3K9me3 modification at ES cell bivalent domains is dependent on the activity of the histone methyltransferase SetDB1. There is also evidence that the PRC2 protein Suz12 interacts with the H3K9 methyl transferase Suv39h1 and promotes H3K9 methylation in differentiated cells but not in undifferentiated ES cells (de la Cruz et al., 2007).

H3K9me3 and H3K27me3 can also occur in conjunction with the adjacent phosphorylated S10 and S28 residues on the same H3 tail, generating double methyl/phospho modifications. Phosphorylation of H3S10 by the Aurora B kinase, together with trimethylation of H3K9, generates high levels of the H3K9me3/S10ph double modification on heterochromatin during the G2 stage of the cell cycle, which then spreads along the entire chromosome at the onset of mitosis. In vitro and in vivo studies show that the presence of S10ph leads to displacement of HP1β from H3K9me3 during condensation of mitotic chromosomes (Fischle et al., 2005). This observation has formed the basis for the methyl-phospho switch hypothesis, which proposes that serine phosphorylation modulates binding of proteins to adjacent methylated lysine residues on the histone tails (Fischle et al., 2003a). The function of H3S10 phosphorylation seems to be context dependent, as H3S10ph is also associated with transcriptionally active promoters in interphase cells, where it is frequently colocalized with peaks of H3 acetylation. This phosphorylation is mediated by the mitogen-activated protein and mitogen- and stress-activated kinases (MSKs; Edmunds and Mahadevan, 2004).

Methyl-phospho switches on the histone H3 tail are not restricted to mitosis. We previously showed that the H3K9me3/S10ph modification is present on facultative heterochromatin in postmitotic plasma cells and also demonstrated that generation of this binary modification in plasma cells requires the activity of the Aurora B kinase (Sabbattini et al., 2007). HP1β does not bind to facultative heterochromatin in plasma cells, and treatment of the cells with the Aurora B inhibitor hesperadin partially reversed this block. Chromatin immunoprecipitation (ChIP) analysis also showed that the binary H3K9me3/S10ph modification marks silent genes in differentiated mesenchymal stem cells, although the identity of the kinase that generates the phospho component of the double modification in these cells was not determined (Sabbattini et al., 2007). Phosphorylation of H3S28 occurs in conjunction with H3K27 methylation during neural differentiation of human teratocarcinoma cells, where it promotes gene activation by displacement of the Polycomb proteins (Gehani et al., 2010).

Here we investigate the roles of H3 methyl-phospho modifications in developmental gene silencing and show that H3K9me3/S10ph marks Polycomb-regulated genes in conjunction with H3K27me3 in differentiated B cells and mesenchymal cells but not in ES cells. We also show that the presence of the H3K9me3/S10ph mark reduces the level of paused RNAPIIS5ph and Ezh1 at Polycomb-regulated promoters. Our results provide evidence for the occurrence of a methyl-phospho switch at Polycomb-regulated genes during differentiation that fine-tunes silencing and contributes to the establishment of an epigenetic profile that is antagonistic to the presence of paused RNAPII.

RESULTS
To characterize the contributions of H3 methyl-phospho modifications to the epigenetic landscape of differentiated cells, we used three different cell systems. Mouse embryonic stem cells provide a well-defined cell culture model representing the undifferentiated pluripotent cells of the inner cell mass in preimplantation blastocysts. Cultured C3H10T1/2 mesenchymal stem cells were induced to differentiate into postmitotic osteoblasts (see Materials and Methods), and primary resting B cells were isolated from mouse spleen and activated for 3 d with lipopolysaccharide (LPS) to provide an example of a cycling differentiated cell type. The double H3K9me3/S10ph modification was analyzed using a commercially available antibody, and the H3K27me3/S28ph modification was detected using an antibody that was raised by injection of a modified peptide into rabbits (described in Materials and Methods). Characterization of the specificities of both antibodies is detailed in Supplemental Figure S1.

The H3K9me3/S10ph double modification is preferentially enriched on Polycomb-regulated genes
We showed previously that the H3K9me3/S10ph double modification is associated with repressed genes in differentiated C3H10T1/2 cells (Sabbattini et al., 2007). To further characterize the distribution of H3K9me3/S10ph in these cells and establish whether it colocalizes with other silencing marks, we carried out ChIP using an antibody against H3K27me3 and compared it with results obtained for H3K9me3/S10ph and H3K9me3 alone (Sabbattini et al., 2007). The precipitated DNA was hybridized to a NimbleGen tiling microarray covering a 2-Mb gene-dense region of mouse chromosome 3. The probed region contains 68 annotated genes and includes cell-type-specific genes with different tissue specificities interspersed with constitutively expressed housekeeping genes. The pattern of enrichment for H3K9me3/S10ph showed striking colocalization with regions of repressed chromatin that were enriched for H3K27me3 (Figure 1A), suggesting that the H3K9me3/S10ph double modification is associated with gene silencing by the Polycomb proteins. The same regions have very low levels of the single H3K9me3 modification (Figure 1A) and show no enrichment for the H3K27me3/S28ph double modification (Figure 1B). These results confirm the presence of a specific and novel combination of H3K9me3/S10ph and H3K27me3 without accompanying S28 phosphorylation at Polycomb-target genes in differentiated mesenchymal cells. They also strongly suggest that there is cross-talk between H3K9me3 and H3K27me3.
FIGURE 1: The H3K9me3/S10ph double modification colocalizes with H3K27me3 at Polycomb-regulated genes in differentiated C3H10T1/2 cells. (A) Tiling microarray analysis spanning 1 Mb of mouse chromosome 3, with repressed genes represented in gray and expressed genes shown in purple. The profile of H3K27me3 in differentiated C3H10T1/2 cells is compared with our previously published data for H3K9me3/S10ph and H3K9me3 (Sabbattini et al., 2007). Domains of enrichment of H3K9me3/S10ph and H3K27me3, corresponding to log2 ratios > 0, are shadowed in yellow. Data are represented as the scaled log2 ratio (pull down/input) of the hybridization signal for the DNA.
FIGURE 2: Inhibition of MSK1/2 and Aurora B reduces the levels of H3K9me3/S10ph on repressed genes. (A) ChIP analysis of differentiated C3H cells treated with H89 (top) or AZD1152 (bottom). Results are expressed as ratio of the percentages of input chromatin immunoprecipitated by H3K9m3/S10ph from treated cells and from control cells treated with vehicle. n = 5 biological replicates for the H89-treated cells, n = 2 for cells treated with 100 nM and 1 µM AZD1152, and n = 4 for cells treated with 500 nM AZD1152. The red line corresponds to a ratio of 1, which represents the value for the control cells. Statistical significance of the reductions observed after H89 treatment was assessed by paired t test. (B) Analysis of the levels of H3K9me3/S10ph at selected genes in differentiated MEFS derived from MSK1 and MSK2 double-knockout (MSK1/2 dko) mice relative to wt cells. n = 2. The silent genes used in this study were selected because they are representative of the following categories: tissue-specific repressed genes located in a gene-dense, 2-Mb region of chromosome 3, chosen as a model of chromosomal organization (Fcr11, Fcrl5, Insrr, Nes, Hcn3, Ntrk, Hpln2, Bcan, Pklr); genes previously known to be silenced by Polycomb complexes (Foxb2, Bmp2, Six1, Lef1, HoxA10, HoxA11; Bernstein et al., 2006b); genes identified by the mouse gene promoter array described in this study in Supplemental Table S1 as being highest H3K9m3/S10ph immunoprecipitated with the indicated antibody. (B) ChIP analysis was carried out on chromatin from differentiated C3HT101/2 mesenchymal cells and resting B cells using anti-H3K27me3/S28ph (black histograms) and anti-H3K9me3/ S10ph (purple histograms). Immunoprecipitated chromatin was analyzed with primers for the promoters of a panel of silent and active genes. Differences between the panels of genes selected for analysis for each cell type reflect differences in expression profiles between the two cell types. Bars, mean ± SD. n = 2. (C) Examples of profiles extracted from the top 300 promoter signals for H3K9me3/S10ph obtained using the NimbleGen 24,000 mouse promoter array. The promoters of the Hoxb and Hoxa genes shows peaks of enrichment for both H3K9m3/S10ph and H3K27me3 (red peaks, high probability, false discovery rate [FDR] ≤ 0.05; yellow peaks, intermediate probability, FDR > 0.1 and ≤ 0.2). Peaks were obtained using the NimbleGen default algorithm (www.nimblegen.com/products/lit/nimblescan2 .3users-guide.pdf). Gene bodies are represented by colored bars with the ‘5’ ends shown in white.

Multiple kinase are involved in generating the H3K9me3/ S10ph modification in differentiated cells

Kinases known to be capable of phosphorylating H3S10 include Aurora B, MSK1 and MSK2, PKA, RSK2, and PIM1. To determine which kinase or kinases generate the H3K9me3/S10ph modification at Polycomb-repressed genes, we treated differentiated C3H cells with a panel of kinase inhibitors. Incubation with H89, which is a potent inhibitor of MSK1/2 (Edmunds and Mahadevan, 2004; Vermeulen et al., 2009), resulted in reductions of around fourfold in enrichment for H3K9me3/S10ph at a number of silent genes (Figure 2A). Because H89 is known to inhibit other kinases in addition to MSK1/2, we isolated primary mouse embryonic fibroblasts (MEFS) from MSK1/2 double-knockout (MSK1/2-dko) mice (Wiggin et al., 2002). MSK1/2-dko and isogenic wild-type (wt) MEFS were induced to differentiate into osteoblasts (Mukherjee et al., 2010), and the levels of H3K9me3/S10ph were analyzed at Polycomb-repressed genes. The analysis of H3K9me3/S10ph in differentiated MSK1/2-dko MEFS showed reduction of ~25% in the levels of H3K9me3/S10ph with respect to wt MEFS (Figure 2B).

The reduction of H3K9me3/S10ph in MSK1/2-dko cells shows that the MSK1/2 kinases are involved in generating the double modification. However, the fact that the effect is smaller than the reduction observed with H89 treatment indicates that other kinases are also involved. Inhibitors of PKA (RpaCAMP), RSK2 (BID1870), and PIM1 (Ly294002) were tested singly or in combination, but none of them gave a significant reduction in the level of H3K9me3/S10ph (Supplemental Figure S3). Treatment with AZD1152, which inhibits the Aurora B kinase with high specificity and does not inhibit levels in differentiated C3HT101/2 cells (Foxd4, Evx1, Hoxb6, HoxA10); and repressed genes that are marked by H3K9me3/S10ph and have very low levels of poised RNApolIIIS5ph in differentiated C3H101/2 cells (Olf399, Olf523, Pdzk1, Nalp10).
MSK1/2, did give a reduction of ∼25% (Figure 2A). These results provide evidence that MSK1/2 and Aurora B contribute to generating the H3K9me3/S10ph modification, but they also indicate that other, unidentified kinases can generate the modification and raise the possibility that there is significant redundancy among the kinases that phosphorylate H3S10 at silent promoters.

The H3K9me3/S10ph double modification is absent from Polycomb-regulated genes in pluripotent ES cells

The data obtained with differentiated mesenchymal cells demonstrate that the H3K9me3/S10ph double modification marks Polycomb-regulated genes. To test whether the mark is present in pluripotent stem cells, we measured the distribution of the double modification at silent and active genes in mouse ES cells. Analyzing the H3K9me3/S10ph modification in cycling cells presents a problem because the modification is very highly enriched and widely distributed on mitotic chromosomes. This generates a background that makes it difficult to use whole-genome approaches, including microarray analysis, to identify regions that show localized enrichment for the double modification in interphase. To circumvent this problem, we used centrifugal elutriation to purify G1-enriched cell populations from ES cell cultures. We also used elutriation to purify cycling G1 cells from primary splenic B cell cultures that had been activated by treatment with LPS. Examples of these purifications are shown in Supplemental Figure S4. Staining of unsynchronized cell populations with the anti-H3K9me3/S10ph antibody shows a clear distinction between the relatively low levels of staining observed in G1/S and the strongly stained G2/M cells generated by enrichment of the modification on pericentric heterochromatin and across mitotic chromosomes. The high-staining G2/M cells were almost entirely absent from the elutriated G1-enriched cell populations (Supplemental Figure S4).

The chromatin precipitated from the G1-enriched cells was hybridized to an Agilent oligonucleotide tile microarray covering the 2-Mb gene-dense region of mouse chromosome 3. ChIP profiles across part of the region that contains both active and silent genes are shown in Figure 3. Inspection of the enrichment profiles shows that domains of H3K27me3 are present in ES cells at the promoters of the neurotrophic tyrosine kinase receptor 1 (Ntrk1) gene, the insulin receptor–related receptor (Insr) gene, the cellular retinoic acid–binding protein II (Crabp2) gene, and the Nestin gene. Several of these genes (Ntrk, Insr, and Crabp2) have bivalent histone modification patterns in ES cells and also show evidence of bivalency in B cells. Strong peaks of H3K9me3/S10ph enrichment were found at the H3K27me3-marked genes in activated B cells, confirming the results obtained in the differentiated mesenchymal cells. Re-ChIP analysis confirmed that the colocalizing H3K27me3 and H3K9me3/S10ph modifications in activated B cells are located on the same allele (Supplemental Figure S5). The strong enrichment obtained for H3K9me3/S10ph at H3K27me3-modified genes in B cells contrasts with the profile obtained in ES cells, where little or no enrichment was observed for the H3K9me3/S10ph modification at any of these loci (Figure 3).

ChIP analysis of the H3K27me3/S28ph double modification gave quite different results compared with the H3K9me3/S10ph modification. H3K27me3/S28ph was absent from Polycomb-regulated genes in G1 activated B cells (Supplemental Figure S6A), whereas Polycomb-regulated genes were found to be enriched for both modifications in quiescent resting B cells (Figure 1B). Immunofluorescence (IF) analysis further confirmed the difference in distribution of H3K9me3/S10ph and H3K27me3/S28ph. Strong IF signals were obtained for both double modifications in resting B cells and on metaphase chromosomes in activated B cells, whereas IF detected only the H3K9me3/S10ph modification in G1/S/G2 activated B cells and in postmitotic plasma cells (Supplemental Figure S6B). These different patterns suggest that the H3K9me3/S10ph and H3K27me3/S28ph modifications have different regulatory roles during cell differentiation.

Evidence for a developmentally regulated methyl-phospho switch at Polycomb-regulated genes

Bilodeau et al. (2009) reported that a significant proportion (47%) of bivalent domains in mouse ES cells are also marked by H3K9me3. We compared their data set with the cohort of genes from this study that showed high levels of enrichment for H3K9me3/S10ph and H3K27me3 in differentiated C3H mesenchymal cells. Of the 667 annotated genes described by Bilodeau et al. (2009) as being enriched for both H3K9me3 and H3K27me3 in ES cells, 42% are marked by the H3K9me3/S10ph-H3K27me3 combination in differentiated C3H cells (Figure 4). In contrast, H3K9me3/H3K27me3 without the accompanying H3S10ph modification is present in C3H cells at only 2.6% of the H3K9me3-marked bivalent domains that Bilodeau et al. (2009) identified in ES cells (Figure 4). Comparison of our results with their data set provides evidence that a high proportion of the genes that are marked by H3K27me3 and H3K9me3 in ES cells are subject to additional modification through a methyl-phospho switch in differentiated mesenchymal cells. Such a switch has the potential to affect protein binding to H3K9me3. However, the fact that a significant proportion of genes that lack H3K9me3 in ES cells acquire H3K9me3/S10ph during differentiation indicates that H3K9me3/S10ph is also generated through de novo methylation of H3K9 as differentiation progresses.

Marking by H3K9me3/S10ph is associated with reduced levels of RNAPII55Ph at Polycomb-regulated genes in differentiated cells

Stock et al. (2007) described the presence of RNA polymerase II phosphorylated at serine 5 (RNAPII55ph) at the promoters and within the coding regions of bivalently marked repressed genes in ES cells. The unusual modification profile and distribution of the RNAPII55ph on these genes led to the hypothesis that the polymerase is paused in readiness for transcriptional activation in response to appropriate signals. We compared the distribution of RNAPII55ph with enrichment patterns for H3K27me3 and the double H3K9me3/S10ph modification in ES cells, activated B cells, and differentiated mesenchymal cells (Figures 3 and 5A). Genes that are enriched for H3K27me3 in ES cells (Ntrk1, Crabp2, Nestin, Bcan, Hpln2) showed strong positive signals for RNAPII55ph close their 5’ ends. In contrast, the same genes, which are marked by the H3K27me3-H3K9me3/S10ph combination in B cells, showed a near absence of RNAPII55ph in these cells (Figure 3). Several of the genes that lacked RNAPII55ph in B cells were bivalent in these cells (see, e.g., the H3K4me3 and H3K27me3 profiles for Crabp2, Nestin, and Brevican). Analysis using the 8WG16 antibody, which detects hypophosphorylated and intermediately phosphorylated RNA PolII (Stock et al., 2007), gave very low signals, indicating a general absence of RNA PolII from these genes (Supplemental Figure S7). ChIP analysis of differentiated C3H cells also showed that RNAPII55ph was absent from repressed genes that were enriched for H3K27me3 in these cells (Figure 5A). These results show that the presence of the H3K9me3/S10ph double modification correlates with a substantial reduction in the level of the paused RNAPII55ph at bivalent and nonbivalent promoters that are marked by H3K27me3 in differentiated cell types.
FIGURE 3: H3K9me3/S10ph is absent from Polycomb-regulated genes in pluripotent ES cells and correlates with loss of paused RNAPII S5ph in activated B cells. Enrichment profiles of part of the 2-Mb, gene-dense region of mouse chromosome 3 in ES cells and activated B cells. The analysis was performed using tiled oligonucleotide microarray chips from Agilent (see the Supplemental Methods for details). Hybridization data were analyzed and visualized using DNA Analytics 4.0.85. For reasons of clarity, the alignment line between the traces was removed. Peaks of enrichment (orange squares) were obtained with the Whitehead per-array neighborhood model with the following settings: custom defined f-value, 0.2; maximum distance for two probes to be considered as neighbor, 1000 base pairs; a probe is considered bound if \( P(X|\text{bar}) < 0.05 \); central probe has \( P(X) = 0.05 \); and at least one of the neighboring probe has \( P(X) = 0.1 \) or at least one neighbor has \( P(X) < 0.05 \). For H3K9me3/S10ph the hybridization was carried out with ChIP DNA from elutriated cells in the G1 phase of the cell cycle. Gene bodies are represented by colored bars with the 5' ends shown in white. Repressed and active genes are colored gray and purple, respectively. Crabp2 is shown in green to indicate that it is expressed at low levels in ES cells. Blue boxes above the genes represent alternative transcripts. Regions containing repressed genes are indicated by dashed boxes.
The ability of H89 to substantially reduce the level of K9me3/S10ph allowed us to test whether the presence of the double modification is causally linked to the low levels of the paused RNA Pol II at Polycomb-regulated promoters in differentiated C3H cells. ChIP analysis showed that reduced enrichment for H3K9me3/S10ph after inhibition with H89 is accompanied by a significant increase in the binding of RNA Pol II to Polycomb-regulated promoters during differentiation. In line with this observation, the decrease in H3K9me3/S10ph observed in MSK1/2 KO MEFs also correlates with increased binding of RNA Pol II to repressed genes (Supplemental Figure S8). These findings provide evidence that the H3K9me3/S10ph modification is involved in displacing poised RNA Pol II from Polycomb-regulated promoters during differentiation.

**Binding of Polycomb proteins to H3K9me3 is blocked by H3S10 phosphorylation**

Polycomb proteins have been shown to bind to H3K9me3 in addition to their canonical binding to H3K27me3 (Fischle et al., 2003b; Bernstein et al., 2006b; Margueron et al., 2009; Kaustov et al., 2011). It has been suggested that the binding to H3K9me3 synergizes with binding to H3K27me3 to promote Polycomb recruitment to the H3 tail (Ringrose et al., 2004). Our observations raise the possibility that phosphorylation of H3S10 could modulate this synergistic effect. To investigate this possibility, we analyzed binding of Polycomb proteins to H3 peptides containing the H3K9me3 and H3K9me3/S10ph modifications by surface plasmon resonance ( SPR). The SPR assay was used to investigate the binding efficiency of recombinant Cbx4, Cbx7, and Cbx8 to H3 peptides containing K9me3, either alone or in conjunction with S10ph. Our results show that phosphorylation of S10 drastically reduced the interaction of the Cbx proteins with the K9me3 (Figure 6A).

We also investigated the effect of S10ph on the binding of the PRC2 proteins Ezh1 and Ezh2 to H3K9me3. Phosphorylation was unsuitable for this purpose, as binding of these proteins to histone H3 outside the context of the PRC2 complex is very inefficient. We therefore used a peptide capture assay to compare binding of Ezh1- and Ezh2-containing PRC2 complexes to H3K9me3. The results show that phosphorylation of H3S10 strongly reduces binding of both proteins to H3K9me3 (Figure 6B). These results provide support for the hypothesis that S10 phosphorylation forms part of a binary switch that modulates binding of Polycomb proteins to chromatin.

**Dynamic switches in binding of PRC2 components at silent and active promoters during mesenchymal differentiation**

We used quantitative PCR-ChIP and ChIP-on-chip analysis to characterize the in vivo interaction of PRC2 proteins with genes that are marked by the H3K9me3/S10ph-H3K27me3 combination in differentiated C3H mesenchymal cells. The results show that Ezh1 is the major PRC2 H3K27 methyltransferase that is bound to repressed genes in differentiated C3H cells (Figure 5 and Supplemental Figure S9). In contrast, little or no binding of Ezh2 is observed at repressed genes.

To test whether phosphorylation of H3S10 functions in vivo as a modulator of Ezh1 and Ezh2 binding to repressed genes, we treated differentiated C3H cells with H89. We then used ChIP to compare binding of Ezh1 and Ezh2 at selected Polycomb-repressed genes in the H89-treated cells with the binding levels in untreated cells (Figure 6C). Binding of Ezh1 showed a mean increase after H89 treatment that ranged from 1.5- to 3-fold and was statistically significant (analysis of variance, p = 0.0007). Binding of Ezh2 to the repressed genes remained low and was not altered by H89 treatment (Figure 6C). These data led us to conclude that Ezh1 is the major H3K27 methyltransferase that binds to repressed genes in differentiated mesenchymal cells. They also indicate that binding of Ezh1 to Polycomb-repressed genes is reduced by the presence of the S10ph modification in differentiated cells.

**DISCUSSION**

The Polycomb proteins play key roles in maintaining transcriptional repression at various stages of development and cell differentiation. In the early embryo, this involves poising of genes for activation, whereas the later stages are believed to involve fixing of transcriptional states in differentiated cells. The results described in this article identify significant changes in the epigenetic landscape of Polycomb-regulated genes that occur during differentiation of mammalian cells. In particular, we describe a novel combination of the binary histone H3K9me3/S10ph modification with Polycomb-associated H3K27me3. In differentiated mesenchymal cells and B cells, these three histone modifications combine to mark Polycomb-regulated genes, whereas in pluripotent ES cells, the H3K9me3/S10ph double modification is largely absent from genes that are marked by H3K27me3. It is intriguing that H3S10ph in conjunction with acetyl-H3K9 is associated with gene activation through binding of 14-3-3 proteins (Winter et al., 2008), whereas our results indicate that the same modification in combination with H3K9 methylation acts to reinforce silencing. This finding provides further evidence of a combinatorial histone code in which a given modification can participate in a number of different combinations that give rise to radically different functional outcomes.

Our results show that repressed genes that encode developmental transcriptional regulators are enriched for the H3K9me3/S10ph-H3K27me3 combination in differentiated cells. This observation suggests that acquisition of the H3K9me3/S10ph modification could be involved in fixing cellular identity during the later stages of differentiation. Use of inhibitors and knockout cells indicates that the phosphorylation of H3S10 that generates the H3K9me3/S10ph modification is partly mediated by MSK1/2 and Aurora B. However, our data also suggest that there is a degree of
redundancy with other, unidentified kinases also able to generate the double modification in differentiated cells. This raises interesting questions about the nature of the signaling pathways that lead to generation of the double modification and suggests that the presence of the H3K9me3/S10ph modification at repressed genes could represent a shared endpoint for different signaling pathways that are involved in fixation of repressed states in a number of differentiated cell types.

Our results and those of Bilodeau et al. (2009) demonstrate that a proportion of the genes that acquire the double H3K9me3/S10ph modification in differentiated mesenchymal cells are already marked by H3K9me3 in ES cells. This suggests that the double modification arises from a bona fide methyl-phospho switch at these genes during differentiation and cell commitment. However, our data also suggest that de novo methylation of H3K9 and phosphorylation of H3S10 are responsible for generating the H3K9me3/S10ph modification at some Polycomb-regulated genes during development. This is likely to be linked to shifts in gene expression patterns as cells differentiate, an explanation that is supported by the observation that bivalent domains are lost and acquired at developmentally regulated genes during differentiation of neural cells (Mohn et al., 2008).
A key feature of the poised state of gene expression observed in ES cells is the presence of the serine 5–phosphorylated form of RNAPII at the 5′ ends of developmentally regulated genes (Stock et al., 2007). We show that reducing the level of H3K9me3/S10ph at repressed genes in differentiated mesenchymal cells by treatment with H89 increases the level of RNAPIIS5ph at these genes. This provides further evidence that the H3K9me3/S10ph modification is associated with the transition from a poised to a fully repressed state. The mechanism behind the effect of the H3K9me3/S10ph modification on RNAPIIS5ph binding is unclear. However, phosphorylation of H3S10 has been shown to displace binding of a wide range of proteins from H3K9me3 (Fischle et al., 2005; Vermeulen et al., 2010). Our results show that the presence of the double H3K9me3/S10ph modification reduces binding of Ezh1 to repressed genes. In vitro binding studies and in vivo peptide competition studies suggest that Polycomb proteins can bind efficiently to H3K9me3.
H3K9me3/S10ph modulates Pol II poising

MATERIALS AND METHODS

Cell culture
Isolation of resting B cells from mouse spleen and activation with LPS were carried out as previously described (Sabbattini et al., 2007). C3H10T1/2 mesenchymal stem cells were expanded in DMEM medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM GlutaMAX, 2 mM nonessential amino acids, and 2 mM sodium pyruvate. Differentiation into osteoblasts was induced as described in Sabbattini et al. (2007), except that β-glycerol phosphate was omitted from the medium. For kinase inhibition, 500 nM AZD1152 (Astra Zenica, Alderley Park, Macclesfield, Cheshire, UK) and H89 (Sigma-Aldrich, St. Louis, MO) were added to the differentiation medium for 7 h. Different H89 preparations showed variable potency in inhibiting MSK1/2. Therefor[e several concentrations of inhibitor were tested for each experiment. Concentrations of H89 found to be effective in reducing H9K9me3/S10ph levels were between 3 and 20 µM.

Centrifugal elutriation
G1 cell populations of mouse embryonic stem cells and LPS-activated B cells were obtained by means of centrifugal elutriation in a

FIGURE 7: Model describing the role of the H3K9me3 and H3K9me3/S10ph modifications in polycomb recruitment and gene silencing. In pluripotent ES cells (top), many bivalent genes are also marked by H3K9me3, which binds PRC2 with higher affinity than H3K27me3. The synergy between H3K9me3 and H3K27me3 enhances polycomb binding. In differentiated cells (bottom), phosphorylation of H3S10 blocks binding of PRC2 to H3K9me3 and reduces overall levels of Polycomb binding to genes that are marked by H3K27me3. This contributes to reducing the levels of paused RNAPII5ph at these genes. The presence of the H3K9me3 modification also blocks acetylation of H3K9 and formation of the H3K9ac/S10ph modification, which recruits 14-3-3 proteins to active promoters.

(Ringrose et al., 2004; Margueron et al., 2009; Xu et al., 2010), suggesting a model in which synergy between H3K9me3 and H3K27me3 enhances the relatively low binding affinity of Polycomb proteins for both modifications (Figure 7). The increase in Ezh1 binding after reduction of the levels of the H3K9me3/S10ph by treatment with the kinase inhibitor H89 supports the idea that part of the function of S10 phosphorylation is to modulate the level of Polycomb binding. Ezh1 has been shown to interact with RNA Pol II at active genes in differentiating myoblasts, raising the possibility that the level of Ezh1 binding modulates the level of paused RNAPII5ph at repressed genes in differentiated cells (Figure 7).

Although an association between reduced binding of a Polycomb protein and more stable silencing might seem counterintuitive, it is becoming increasingly clear that developmental silencing of gene expression by Polycomb proteins is often associated with maintenance of gene plasticity at the pluripotent and multipotent stages of cell differentiation. Our results suggest that changes in histone modifications have a role in modulating Polycomb binding and converting the relatively plastic silencing that is observed early in development into a more stable repressed state in differentiated cells. These observations highlight a growing shift in the Polycomb paradigm from a purely repressive function for Polycomb proteins toward a scenario in which they are highly versatile interactors with the transcriptional machinery that can mediate silencing, gene poising, or transcriptional activation, depending on the context.

MATERIALS AND METHODS

Cell culture
Isolation of resting B cells from mouse spleen and activation with LPS were carried out as previously described (Sabbattini et al., 2007). C3H10T1/2 mesenchymal stem cells were expanded in DMEM medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM GlutaMAX, 2 mM nonessential amino acids, and 2 mM sodium pyruvate. Differentiation into osteoblasts was induced as described in Sabbattini et al. (2007), except that β-glycerol phosphate was omitted from the medium. For kinase inhibition, 500 nM AZD1152 (Astra Zenica, Alderley Park, Macclesfield, Cheshire, UK) and H89 (Sigma-Aldrich, St. Louis, MO) were added to the differentiation medium for 7 h. Different H89 preparations showed variable potency in inhibiting MSK1/2. Therefore several concentrations of inhibitor were tested for each experiment. Concentrations of H89 found to be effective in reducing H9K9me3/S10ph levels were between 3 and 20 µM.

Centrifugal elutriation
G1 cell populations of mouse embryonic stem cells and LPS-activated B cells were obtained by means of centrifugal elutriation in a
Jean-E, S. (2008). Cell cycle synchronization of animal cells and nuclei by centrifugal elutriation. Nat Protoc 3, 663–673.

Banfalvi G (2008). Cell cycle synchronization of animal cells and nuclei by centrifugal elutriation. Nat Protoc 3, 663–673.

Bernstein BE et al. (2006a). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326.

Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD (2006b). Mouse Polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol 26, 2560–2569.

Bilodeau S, Kagey MH, Frampton GM, Rahl PB, Young RA (2009). SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state. Genes Dev 23, 2484–2489.

Boyer LA et al. (2006). Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349–353.

de la Cruz CC, Kirmizis A, Simon MD, Isono K-I, Koseki H, Panning B (2007). The polycomb group protein SUZ12 regulates histone H3 lysine 9 methylation and H1 alpha distribution. Chromosome Res 15, 299–314.

Edmunds JW, Mahadevan LC (2004). MAP kinases as structural adaptors and enzymatic activators in transcription complexes. J Cell Sci 117, 3715–3723.

Ezhkova E, Lien W-H, Stokes N, Pasoli HA, Silva JM, Fuchs E (2011). EZH1 and EZH2 cоговер histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev 25, 485–498.

Fischle W, Tseng BS, Dormann HL, Ueberheide BM, Garcia BA, Shabanowitz J, Hunt DF, Funabiki H, Allis CD (2005). Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature 438, 1116–1122.

Fischle W, Wang Y, Allis CD (2003a). Binary switches and modification cascades in histone biology and beyond. Nature 425, 475–479.

Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD, Khorasanizadeh S (2003b). Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 for Polycomb and HP1 chromodomains. Genes Dev 17, 1870–1881.

Gehani SS, Agrawal-Singh S, Dietrich N, Christophers NS, Heln K, Hansen K (2010). Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3/2 phosphorylation. Mol Cell 39, 886–901.

Huang DW, Sherman BT, Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44–57.

Jenuwein T, Allis C (2001). Translating the histone code. Science 293, 1074–1080.

Kaul Gast L et al. (2011). Recognition and specificity determinants of the human cdx chromodomains. J Biol Chem 286, 521–529.

Margueron R et al. (2009). Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762–767.

Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, Schübeler D (2008). Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30, 755–766.

Moussa K, Zare H, Wang AH, Sartorelli V (2011). Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol Cell 45, 255–262.

Mukherjee A, Wilson EM, Rotwein P (2010). Selective signaling by Akt2 promotes RNA polymerase II elongation. Mol Cell 45, 255–262.

Nouy P et al. (2006). Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8, 532–538.

Ringrose L, Ehret H, Paro R (2004). Distinct contributions of histone H3 lysine 9 and 27 methylation to locus-specific stability of polycomb complexes. Mol Cell 16, 641–653.

Sabbattini P, Canzonetta C, Sjoberg M, Nikic S, Georgiou A, Kembell–Cook G, Auner HW, Dillon N (2007). A novel role for the Aurora B kinase in epigenetic marking of silent chromatin in differentiated postmitotic cells. EMBO J 26, 4657–4669.
Vermeulen M et al. (2010). Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 142, 967–980.

Vermeulen L, Berghe WV, Beck IME, De Bosscher K, Haegeman G (2009). The versatile role of MSKs in transcriptional regulation. Trends Biochem Sci 34, 311–318.

Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JSC (2002). MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22, 2871–2881.

Winter S, Simboeck E, Fischle W, Zupkovitz G, Dohnal I, Mechtler K, Ammerer G, Seiser C (2008). 14-3-3 proteins recognize a histone code at histone H3 and are required for transcriptional activation. EMBO J 27, 88–99.

Xu C et al. (2010). Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc Natl Acad Sci USA 107, 19266–19271.

Xu K et al. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338, 1465–1469.
A H3K9/S10 methyl-phospho switch modulates Polycomb and Pol II binding at repressed genes during differentiation

Pierangela Sabbattini\textsuperscript{1,4}, Marcela Sjoberg\textsuperscript{1,4}, Svetlana Nikic\textsuperscript{1,4}, Alberto Frangini\textsuperscript{1}, Per-Henrik Holmqvist\textsuperscript{1}, Natalia Kunowska\textsuperscript{1}, Tom Carroll\textsuperscript{1}, Emily Brookes\textsuperscript{2}, Simon J. Arthur\textsuperscript{4}, Ana Pombo\textsuperscript{2} and Niall Dillon\textsuperscript{1,*}

\textsuperscript{1}Gene Regulation and Chromatin Group and \textsuperscript{2}Genome Function Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN. \textsuperscript{4}MRC Protein Phosphorylation Unit, Sir James Black Complex, University of Dundee, Dundee DD1 5EH, Scotland, U.K.

SUPPLEMENTAL MATERIALS

This supplement contains:
Supplementary Figures
Supplementary Material and Methods
Supplementary References
FIGURE S1: Validation of the specificities of the anti-H3K9me3/S10ph antibody (upper panel) and the anti-H3K27me3/S28ph antibody (lower panel). Antibody specificities were analysed by ELISA using the indicated peptides. The y-axes represent the percentage cross-reaction relative to the value for the cognate peptide sequence for each antibody (shown as 100%). Bars = mean ± SD; n = 2. The similarity of the amino acid sequences surrounding H3K9/S10 and H3K27/S28 makes it important to assess whether there is cross-reaction between antibodies.
recognising the H3K9me3/S10ph and H3K27me3/S28ph modifications. For the two antibodies used in this study, specificity was initially assessed using ELISA carried out with peptides containing single and double modifications. The two antibodies raised against the binary H3K9me3/S10ph and H3K27me3/S28ph modifications showed little or no cross-reaction with peptides containing any of the single H3 modifications (H3K9me3, H3K27me3, H3S10ph, H3S28ph). Each of the two antibodies also showed predominant binding to its cognate binary modification peptide. However there was a weak cross-reaction (~20%) between the anti-H3K9me3/S10ph antibody and the H3K27me3/S28ph peptide. Analysis of the anti-H3K27me3/S28ph antibody also showed approximately 30% cross-reaction with the H3K9me3/S10ph peptide in the ELISA assay, despite having been depleted with the H3K9me3 peptide.

The cross-reaction between the two antibodies that was observed in the ELISA could make it difficult to assess the levels of the two binary modifications in ChIP assays that make use of the individual antibodies if both modifications are present together on the same region of chromatin. However, comparison of the binding profiles obtained with the two antibodies has made it possible to measure the levels of both binary modifications. The results of the ChIP analysis show that co-existence of the two binary modifications is only observed in resting B cells and demonstrate that the H3K27me3/S28ph modification is absent from Polycomb regulated genes in G1 activated B cells. Similar results were obtained for differentiated C3H cells (Fig. 1C and 5A). Interestingly, the anti-H3K27me3/S28ph antibody does not show any evidence of cross-reaction with the H3K9me3/S10ph modification at silent genes in G1 activated B cells or in differentiated mesenchymal stem cells, despite the presence of high levels H3K9me3/S10ph at these genes. This suggests that the ELISA results might be overestimating the degree of cross reaction that is observed in native chromatin.
**FIGURE S2:** The H3K9me3/S10ph-H3K27me3 combination preferentially marks promoters of genes encoding transcriptional regulators in differentiated C3H cells. ChIP DNA was hybridised to the Nimblegen 24,000 promoter array. The top 20% of promoters enriched in two biological replicates for each of the indicated histone modifications were analysed for gene ontology clustering using DAVID [http://david.abcc.ncifcrf.gov](http://david.abcc.ncifcrf.gov) (Huang et al, 2009).

(A) Number of promoters with overlapping H3K27me3 and H3K9me3/S10ph and H3K9me3 modifications of genes that encode transcriptional regulators or receptors linked to signal transduction. Percentages refer to the number of promoters enriched for H3K27me3 that also show enrichment for either H3K9me3/S10ph or H3K9me3 only (summarised in the bar chart on the right).

(B) Gene ontology clustering indicates that H3K9me3/S10ph and H3K9me3 mark genes with different functions, with H3K9me3/S10ph preferentially found on transcription and developmental regulators and H3K9me3 found on genes encoding receptors involved in signal transduction. N corresponds to the number of annotated genes among the top 20% fraction of enriched promoters for the indicated histone modification.

The gene ontology analysis showed a strong enrichment of H3K9me3/S10ph on the promoters of genes that are involved in transcriptional and developmental regulation. Of the genes that are classified as transcriptional regulators and are marked by H3K27me3, 69% also have the H3K9me3/S10ph modification. In contrast, the single H3K9me3 modification without the adjacent H3S10ph is found at only 3% of the transcriptional regulator genes that are marked by H3K27me3 (A). The analysis also showed that the H3K9me3/S10ph modification is underrepresented on promoters of genes that encode signalling receptors (A and B). Instead, the promoters of these genes are marked by either H3K27me3 (23%), or H3K9me3 (51%), with only 9% having the two marks co-localised on the promoters. Together these results reveal striking differences in the combinations of H3 modifications that are found at promoters of different types of gene. They suggest that the double H3K9me3/S10ph modification forms part of a histone code that differentially repressed genes that have different functions during cell differentiation.
FIGURE S3: Effect of kinase inhibitors on H3K9me3/S10ph levels.
Chip analysis for H3K9me3/S10ph was carried out on chromatin from differentiated C3H10T1/2 cells treated with RpcAMP (10µM), LY294002 (30µM), BID1870 (10µM), AZD1151 (500nM) or vehicle (DMSO) for 14 hours. Levels are expressed as the ratio of the amount of double H3K9me3/S10ph modification detected in cells treated with inhibitors relative to cells treated with vehicle. The red line corresponds to a ratio of 1 and represents the value for the control cells. Bars = mean ± SD. n = 2 biological replicates for each inhibitor treatment.
**FIGURE S4:** Examples of FACS analysis of ES cells and activated B cells stained with propidium iodide carried out on non-elutriated and elutriated cells in the G1 phase of the cell cycle. Cell fractions isolated by centrifugal elutriation (see methods) were stained with propidium iodide and analysed for DNA content by FACS. ES cells have an unusual cell cycle profile with a high proportion of the cells showing S and G2/M staining profiles. The elutriated ES cell fraction used for the analysis was enriched for G1, but also contained some S-phase cells. Immunofluorescence staining with anti-H3K9me3/S10ph antibody (bottom panels) was used to confirm that the elutriated cell fraction was free of high-staining G2/M cells. Scale bars represent 50µm.
FIGURE S5: Sequential ChIP confirms co-localisation of H3K27me3 and H3K9me3/S10ph on chromatin in G1 activated B cells.
The first ChIP was performed with anti-H3K27me3 (A) and anti-H3K9me3/S10ph (B). Re-ChIP was then carried out on the recovered chromatin using the antibody indicated after the arrow in each graph. The results show that H3K9me3/S10ph co-immunoprecipitates with H3K27me3 and with the PRC2 protein Ezh2 on silent genes in G1 activated B cells. Bars = mean ± SD.
FIGURE S6: Different distributions of the H3K9m3/S10ph and H3K27me3/S28ph double modifications on B cell chromatin. (A) ChIP analysis was carried out on chromatin from LPS-activated B cells using anti-H3K27me3/S28ph (black histograms) and anti-H3K9m3/S10ph (purple histograms). Immunoprecipitated chromatin was analysed with primers for the promoters of a panel of silent and active genes. Bars = mean ± SD. (B) Immunofluorescence analysis of the distribution of H3K9me3/S10ph (left hand panels) and H3K27me3/S28ph (right hand panels) in cells at different stages of B cell development and of the cell cycle. Top panels: isolated resting B cells. Middle panels: In vitro differentiated plasma cells. Bottom panels: Splenic B cells activated for 3 days with LPS. Arrows indicate nuclei of cells in G1/S, G2, or mitosis(M). Scale bars represent 10µm.
**FIGURE S7**: Unphosphorylated RNAPII and RNAPIIS5ph do not bind to regions that are marked by H3K9me3/S10ph in activated B cells. ChIP analysis was carried out using anti-RNAPIIS5ph and the 8WG16 antibody, which recognises hypo-phosphorylated RNAPII. Calculation of peaks of enrichment (orange squares) is described in the legend to Figure 4. Dashed boxes indicate regions containing repressed genes (black rectangles). Purple rectangles = active genes.
**FIGURE S8:** Differentiated MSK1/2 KO MEFs show increased binding of RNAPIIS5ph on repressed genes.

ChIP analysis of H3K9me3/S10ph and RNAPIIS5ph at repressed genes in differentiated MSK1/2 dko MEFs. Values are expressed as the levels of enrichment relative to the levels in wt cells. The red line correspond to ratio of 1, which represents the value for the control cells.
**FIGURE S9**: Ezh1 co-localizes with H3K9me3/S10ph-H3K27me3 at repressed genes in differentiated C3H10T1/2 cells
Upper and lower panels show a microarray analysis of different sections of the 2 Mb region of mouse chromosome 3. Chromatin from differentiated C3H10T1/2 cells was precipitated with the indicated antibodies and hybridised to an Agilent tiling oligonucleotide microarray as described in figure 4. Peaks of enrichment are indicated by orange squares. Dashed boxes indicate regions containing repressed genes.
**Supplementary Table 2.** List of antibodies used in the ChIP assays.

| Antibody                          | Host     | Supplier         | Cat nr.                | Amount used per IP               |
|-----------------------------------|----------|------------------|------------------------|----------------------------------|
| Anti-EZH2                         | rabbit   | Active Motif     | AR-0163-200 (39103)    | 5µg for 100µg of chromatin       |
| Anti-EZH2                         | rabbit   | Active Motif     | 39639                  | 10µl for 400µg of chromatin      |
| Anti-EZH2                         | rabbit   | Active Motif     | 39901                  | 10µl for 400µg of chromatin      |
| Anti-H3K4me3                      | rabbit   | Abcam            | ab8580                 | 2µg for 25µg of chromatin        |
| Anti-H3K27me3                     | mouse    | Abcam            | ab6002                 | 5-10µg for 100µg of chromatin    |
| Anti-H3K9me3/S10ph                | rabbit   | Abcam            | ab5819                 | 5µg for 200µg of chromatin       |
| Anti-Ezh1                         | goat     | Santa-Cruz       | sc-20347               | 8 µg for 400µg of chromatin      |
| Anti-Ezh1                         | rabbit   | Abcam            | ab64850                | 10µg for 400µg of chromatin      |
| Anti-RBP1 CTD phosphorylated on Ser5 | mouse    | Covance          | MMS-128P               | 25µg for 400µg of chromatin      |
| Anti-non phosphorylated RBP CTD (8WG16) | mouse    | Covance          | MMS-126R               | 25µg for 400µg of chromatin      |
| IgG                               | goat     | Santa Cruz       | sc-2018                | 5µg for 100µg of chromatin       |
| Anti-H3K9me3                      | rabbit   | Millipore        | 07-442                 | 5µg for 250µg of chromatin       |
SUPPLEMENTARY METHODS

Generation and purification of the anti-H3K27me3/S28 antibody
The rabbit polyclonal antibody used to detect the H3K27me3/S28ph double modification was generated using the following peptide: KAARK(me3)(ph)APATGG-C. To minimise cross-reactivity with the homologous K9me3/S10ph region, the antibody was immunodepleted by incubation with NeutrAvidin agarose beads (Thermo Scientific) conjugated to a peptide containing the H3K9me3/S10ph epitope (biotin- ARTKQTARK(me3)(ph)TGGKAP-RKQL). Assessment of the specificity of the antibody is described in Figure S1.

Osteogenic differentiation of MEFs
MEFs isolated from wt and MSK1/2 double KO littermates were grown in α-MEM/10% FCS/ 100U penicillin/ 100 µg/ml streptomycin to 50% confluence. For osteogenic differentiation the cells were transferred into osteogenic medium (α-MEM/10% FCS/ 100U penicillin/ 100 µg/ml streptomycin/ 50µg/ml ascorbic acid/ 10mM β-glycerophosphate/50 ng/ml BMP-2. The medium was replaced every 72 h for up to 14 days.

Centrifugal elutriation
Conditions to obtain G1 LPS activated mouse B cells were as follows: Elutriation was carried out on 4 X 10^8 cells after 72 hours of activation with LPS. The cells were suspended in 10 ml of RPMI media supplemented with 1% FBS and loaded into the system at 2300 r.p.m and 4°C, using a starting flow rate of 6 ml/min. G1 mouse B cells were flushed out of the chamber at a flow rate of 10 ml/min. Conditions to obtain G1 mouse ES cells were as follows: 2.5 X 10^8 cells were suspended in 10 ml of PBS supplemented with 1% FBS and loaded into the system at 1800 r.p.m and 4°C, using a starting flow rate of 7 ml/min. G1 mouse ES cells were flushed out of the chamber at a flow rate of 9 ml/min. For both cell types, cell fractions of 200 ml were collected at different flow rates (from 7 to 13 ml/min). Cell cycle stage was assessed by measuring the DNA content using propidium iodide (PI) staining on a Becton Dickinson FACSCalibur Flow Cytometer, using BD CellQuest Pro software.

Chromatin Immunoprecipitation
ChIP analysis was carried out as described by (Szutorisz et al., 2005) with the following modifications. Cells were fixed in medium + 1% formaldehyde for 10 min at 37°C. Formaldehyde-fixed chromatin from 2.5 - 3 x 10^7 cells/ml was sonicated in sonication buffer (50 mM Hepes pH 7.9/ 140 mM NaCl/ 1mM EDTA/ 1% triton X/ 0.1% Na-deoxycholate/ 0.1% SDS/ Complete-mini Roche protease inhibitors/ SIGMA phosphatase inhibitors cocktail 3) using a Diagenode Bioruptor to obtain DNA fragments of around 500 bp. Aliquots of 100-400 µg of sonicated chromatin were subjected to immunoprecipitation in sonication buffer with 5 mg of antibody. For ChIP analysis of resting B cells with the antibodies against H3K9me3/S10ph and H3K27me3/S28ph the protocol described above was used with the following modifications. 10^8 cells were lysed in 10 ml of lysis buffer (10 mM HEPES pH 7.5, 10
mM EDTA, 0.5 mM EGTA and 0.5% Triton) and incubated at 4°C on a rotating platform for 10 minutes. After centrifugation at 1700g, the nuclei were resuspended in 10 ml of nuclei wash buffer (10mM HEPES pH 7.5, 1mM EDTA, 0.5 mM EGTA and 200 mM NaCl) and incubated at 4°C on a rotating platform for 10 minutes. The nuclei were then resuspended in 1ml of lysis/sonication buffer (25 mM Tris pH7.5, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.2% sodium deoxycholate), lysed on ice for 30 minutes and sonicated. The material was centrifuged at 14,000rpm (4°C, 15 min) and the chromatin concentration was measured. For the immunoprecipitation, 70 µl of purified anti-H3K27me3S28ph antibody was coupled to 200 µl of protein G-dynabeads (Invitrogene 100-03D) in wash buffer 1 (50 mM Tris pH8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40 and 1mM EDTA) at 4°C for 4hr on a rotating wheel. The beads-antibody conjugates were washed twice with buffer 1 and subsequently incubated with 200 µg of chromatin at 4°C overnight. After washes and DNA elution, the eluted DNA fragments were treated with 200 µg/ml of proteinase K and purified using the QIAquick PCR purification Kit. Aliquots of 2 µl of 100 µl of immunoprecipitated and input DNA were analyzed by quantitative real-time PCR (qPCR). Amplification (40 cycles) was performed using SYBR Green Jump Start (Sigma). All buffers were supplemented with protease inhibitors cocktail (Roche, Burgess Hill, UK) and phosphatase inhibitors cocktail (Sigma).

**Re-ChIP analysis of H3K27me3 and H3K9me3/S10ph**
For sequential re-ChIP, cross-linked chromatin was immunoprecipitated with the indicated first antibody. Immunocomplexes were eluted with 100 µl of ChIP elution buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 1% SDS) for 10 min at 68°C on a rotating platform (Geisberg and Struhl, 2004). A 10 ml aliquot of eluted chromatin was used for qPCR to evaluate the first ChIP and the residual fraction was diluted 10-fold in dilution buffer (16.7 mM Tris-HCl pH 8.0, 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton, 0.01% SDS). The diluted eluate was divided into equal fractions and the second ChIP was performed under the same conditions as the first, using anti-H3K27me3 or anti-H3K9me3S10ph antibodies. Anti-EZH2 antibody was used as a positive control and anti-IgG as a negative control.

**ChIP-on-chip using Agilent tiling microarrays**
Whole genome amplified DNA (3 mg) was labelled with Cy3 (input) and Cy5 (ChIP DNA) by random priming and hybridized to Agilent microarrays tiled across selected regions of the mouse genome (http://www.chem.agilent.com/cag/ prod/dn/G4410-90020_CGH_Protocol_FFPE1_0.pdf). High frequency repeats were excluded from the array by repeat masking. Agilent scanner and Feature Extraction software were used to obtain feature intensity data. ChIP interactive analysis of the extracted features were performed with the CGH module of the DNA Analytics® software 4.0.85 (Agilent Technologies). Dye bias (Intra-array) and Inter-array median normalization methods were applied. The Whitehead Error Model was applied using the observed spread of negative controls source. The ChIP application used the Whitehead Per-Array Neighbourhood model for peak detection. p-values of p<0.05 for the central probe and its left and right neighbours were used to identify protein-DNA binding interactions (peaks). Two biological replicate ChIP/microarrays were performed for each antibody.
**Peptide pulldown assay**

NIH3T3 cells were harvested, washed once with ice-cold PBS and resuspended in 1 ml sucrose buffer (10 mM Tris pH 8.0, 0.32 M sucrose, 3 mM CaCl2, 2 mM magnesium acetate, 1 mM DTT, 0.1 mM EDTA, 0.2% NP-40 and freshly added protease inhibitors (Roche)) per $10^8$ cells to isolate the nuclei. After 5 min of incubation on ice, the nuclei were pelleted by centrifugation (500g, 5 min., 4°C) and washed once with sucrose buffer without the detergent. The quality of the nuclear preparations was confirmed visually by trypan blue staining. The nuclei were then resuspended in 1 ml lysis buffer (20 mM Hepes, pH 7.9, 25% v/v glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT and freshly added protease inhibitors) per 3 x $10^8$ cells and subjected to 3 cycles of freezing and thawing, followed by centrifugation (10 min, max, 4 deg. C). The supernatant was collected as the nuclear fraction, while chromatin pellets were solubilized by digestion with MNase I (New England BioLabs). The nuclear and chromatin fractions were pooled together, adjusted to 150 mM NaCl and pre-cleared, and used for the peptide capture assay with biotinylated peptides corresponding to aa 1-20 of histone H3 (GL Biochem). The peptides contained the following defined post-translational modifications: trimethylation of lysine K9 alone or in combination with phosphorylation of serine S10. The unmodified peptide was used as a control. The peptide pulldown assay was performed as described in (Wysocka, 2006) with the following modifications. 5x10^7 cells were used per assay. Extracts were incubated at 4°C with 20 µl of NeutrAvidin beads (Pierce) coupled to biotinylated histone peptides. Beads were then washed 5 times with ice-cold wash buffer (20 mM Hepes, pH 7.9, 20% v/v glycerol, 0.2 mM EDTA, 0.2% Triton X-100, 150 mM KCl and freshly added protease inhibitors). Bound proteins were eluted by boiling in Laemmli buffer. Eluted proteins were subjected to SDS-PAGE followed by Western blotting and detection with the antibodies against Ezh1 and Ezh2 (Table II).

**In vitro binding analysis by surface plasmon resonance (SPR)**

Surface Plasmon Resonance was carried out as described in Sabbattini et al., 2007. The assays were performed on a Biacore X instrument (Biacore, Milton Keynes, UK) with Biacore HBS-EP buffer (10 mM Hepes pH 7.4, 0.15M NaCl, 3 mM EDTA, 0.005% Tween 20) at a flow rate of 10 ml/min. 6500 response units (RU) of anti-6X-His monoclonal antibody (Abcam) and 6700 RU of a control anti-RNA pol II monoclonal antibody (kind gift of Laszlo Tora) were immobilised using the Amine Coupling Kit (Biacore) on flow cell 1 and 2 respectively of a CM5 sensor chip. 300 nM 6Xhis-Cbx protein was injected simultaneously over flow channels 1 and 2 followed by injection over both flow channels of 50 mM solutions of peptides for 2 minutes. After the injection, the dissociation of the complex was followed for 180 seconds. Non-phosphorylated peptides were also injected at lower concentrations for comparability to phosphorylated peptide binding. The difference between the increase in RU between flow channel 1 and flow channel 2 was used to measure the specific binding of the peptides to His-Cbx. At least two injections were carried out for each peptide. Data were analysed using Bioevaluation 3.2 software (Biacore).
SUPPLEMENTARY REFERENCES

Geisberg, J.V., and Struhl, K. (2004). Quantitative sequential chromatin immunoprecipitation, a method for analyzing co-occupancy of proteins at genomic regions in vivo. Nucleic Acids Res 32, e151.

Szutorisz, H., Canzonetta, C., Georgiou, A., Chow, C.-M., Tora, L., and Dillon, N. (2005). Formation of an active tissue-specific chromatin domain initiated by epigenetic marking at the embryonic stem cell stage. Mol Cell Biol 25, 1804-1820.

Wysocka, J. (2006). Identifying novel proteins recognizing histone modifications using peptide pull-down assay. Methods 40, 339-343.